Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171686 | 0.88 | KMT2A (0.63) | KMT2AMEN1POLBMTNR1AMTNR1B | |
| SCHEMBL849875 | 0.82 | MEN1 (0.77) | KMT2AMEN1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL12781878 | 0.82 | MEN1 (0.70) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL7334106 | 0.81 | LMNA (0.68) | KMT2AMEN1POLBMTNR1AMTNR1B | |
| SCHEMBL23033141 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1POLBSMN1; SMN2NPC1 | |
| SCHEMBL29573568 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1POLBSMN1; SMN2NPC1 | |
| SCHEMBL17932840 | 0.81 | SMN1; SMN2 (0.62) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL30368270 | 0.80 | KMT2A (0.50) | KMT2AMEN1POLBMTNR1AMTNR1B | |
| SCHEMBL17102381 | 0.80 | SMN1; SMN2 (0.50) | KMT2AMEN1POLBMTNR1AMTNR1B | |
| SCHEMBL30038868 | 0.80 | KMT2A (0.50) | KMT2AMEN1POLBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9730931-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9695132-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20170067168-A1 | PORPHYRIN MOLECULAR CATALYSTS FOR SELECTIVE ELECTROCHEMICAL REDUCTION OF CO2 INTO CO | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9586936-B2 | Heteroarylamine derivatives as protein kinase inhibitors | KOREA INSTITITUE OF SCIENCE AND TECHNOLOGY (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-20160145240-A1 | HETEROARYLAMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-05-26 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | KMT2A 2015/4885MEN1 4187/4885POLB 731/4885 |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885POLB 3726/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | KMT2A 2836/4885MEN1 3606/4885POLB 71/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | KMT2A 2523/4885MEN1 3268/4885POLB 2389/4885 |
| US-20170067168-A1 | PORPHYRIN MOLECULAR CATALYSTS FOR SELECTIVE ELECTROCHEMICAL REDUCTION OF CO2 INTO CO | CYC1, MT-CO2, MT-CO1 | KMT2A 2943/4885MEN1 923/4885POLB 1405/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | KMT2A 2015/4885MEN1 4187/4885POLB 731/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885POLB 3726/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885POLB 3726/4885 |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | KMT2A 2015/4885MEN1 4187/4885POLB 731/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | KMT2A 2523/4885MEN1 3268/4885POLB 2389/4885 |
| US-20160145240-A1 | HETEROARYLAMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K10 | KMT2A 673/4885MEN1 3517/4885POLB 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.